阿曲生坦用于转移性激素难治性前列腺癌。

Atrasentan for metastatic hormone refractory prostate cancer.

作者信息

Murphy G

出版信息

Issues Emerg Health Technol. 2005 Dec(77):1-4.

Abstract

(1) Atrasentan (Xinlay(R)) is an anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists. The orally administered drug is being studied in a subset of patients with advanced prostate cancer. (2) Phase II and III studies evaluating time to clinical and radiographic progression failed to demonstrate a significant benefit with atrasentan versus placebo. (3) The adverse effects, observed more frequently in those treated with atrasentan than in placebo-treated patients, were peripheral edema, rhinitis, headache, infection, dyspnea, and heart failure. (4) Atrasentan's role in the various stages of advanced prostate cancer, and relative to the chemotherapeutic agent docetaxel, has not been determined.

摘要

(1) 阿曲生坦（Xinlay(R)）是一种新型抗癌药物，属于选择性内皮素-A受体拮抗剂。这种口服药物正在一部分晚期前列腺癌患者中进行研究。(2) 评估临床和影像学进展时间的II期和III期研究未能证明阿曲生坦对比安慰剂有显著益处。(3) 与安慰剂治疗的患者相比，接受阿曲生坦治疗的患者更常出现的不良反应有外周水肿、鼻炎、头痛、感染、呼吸困难和心力衰竭。(4) 阿曲生坦在晚期前列腺癌各个阶段的作用以及相对于化疗药物多西他赛的作用尚未确定。